Neurocrine Biosciences (NBIX) Tops Q2 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Neurocrine Bio. (NBIX) PT Raised to $125 at Needham & Company
August 1, 2018 7:16 AM EDTNeedham & Company raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $125.00 (from $110.00) while maintaining a Buy rating.
Analyst Alan Carr commented, "Neurocrine reported $96.9M in 2Q18 Ingrezza sales, above our $85.0M and consensus $84M ests. Mgmt still not providing sales guidance, but... More
Neurocrine Bio. (NBIX) PT Raised to $131 at Baird
August 1, 2018 6:58 AM EDTBaird raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $131.00 (from $122.00) while maintaining an Outperform rating on continued strength in Ingrezza launch.
Analyst Brian Skorney commented, "Neurocrine reported earnings, with net sales of Ingrezza coming in well ahead of expectations at $96.9M.... More
Neurocrine Bio. (NBIX) PT Raised to $135 at Barclays
August 1, 2018 5:38 AM EDTBarclays raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $135.00 (from $100.00) while maintaining a Overweight rating.
... More